SCHEMBL3900151

SCHEMBL3900151

CN1CCc2cc(N(C)C)c(S(=O)(=O)c3ccc(C=O)cc3)cc2CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
HTR6 P50406 11/20 0.38
MAOB P27338 1/20 0.36
MEN1 O00255 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
KMT2A Q03164 1/20 0.35
CYP2A6 P11509 1/20 0.34
CYP2A13 Q16696 1/20 0.34
HTR2C P28335 10/20 0.33
DRD2 P14416 9/20 0.33
DRD3 P35462 9/20 0.33
HTR2A P28223 9/20 0.33
CYP1A2 P05177 2/20 0.33
CYP3A4 P08684 2/20 0.33
CYP2D6 P10635 2/20 0.33
CYP2C9 P11712 2/20 0.33
CYP2C19 P33261 2/20 0.33
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3909295 0.85 HTR2C (0.45) HTR6MEN1MAPTKMT2AHTR2C
SCHEMBL3892958 0.85 LMNA (0.44) HTR6HTR2CDRD2DRD3HTR2A
SCHEMBL14411990 0.82 HTR6 (0.43) HTR6HTR2CDRD2DRD3HTR2A
SCHEMBL5452773 0.82 USP2 (0.42) HTR6HTR2CDRD2DRD3HTR2A
SCHEMBL5453002 0.82 USP2 (0.42) ALDH1A1HTR6GAAKMT2AHTR2C
SCHEMBL5445721 0.81 USP2 (0.41) HTR6MAPTHTR2CDRD2DRD3
SCHEMBL5452896 0.81 HTR2C (0.42) ALDH1A1HTR6HPGDHTR2CDRD2
SCHEMBL5462456 0.81 USP2 (0.41) ALDH1A1HTR6MEN1MAPTKMT2A
SCHEMBL3907770 0.80 MAOB (0.52) ALDH1A1HTR6MAOBHTR2CDRD2
SCHEMBL5459209 0.79 DRD1 (0.43) ALDH1A1GAAHTR2CDRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7504392-B2 2,3,4,5-tetrahydro-1H-3-benzazepines and their medical use GLAXO GROUP LIMITED (GB) 2009-03-17 US disclosed
US-20080269197-A1 antipsychotic agents; phenylsulfonyl compounds; 7-Methoxy-8-(3-phenoxy-benzenesulfonyl)-2,3,4,5-tetrahydro-1H-3-benzazepine; schizophrenia GLAXO GROUP LIMITED 2008-10-30 US disclosed
EP-1511727-B1 AROMATIC SULFONES AND THEIR MEDICAL USE GLAXO GROUP LTD (GB) 2007-02-21 EP disclosed
US-20050261279-A1 Compounds GLAXO GROUP LIMITED (GB) 2005-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269197-A1 antipsychotic agents; phenylsulfonyl compounds; 7-Methoxy-8-(3-phenoxy-benzenesulfonyl)-2,3,4,5-tetrahydro-1H-3-benzazepine; schizophrenia SIGMAR1, CBR3, CBR1 ALDH1A1 2673/4885HTR6 103/4885MAOB 291/4885
US-20050261279-A1 Compounds CBR1, CBR3, OXER1 ALDH1A1 2694/4885HTR6 811/4885MAOB 2012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.